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Protease engineeringThis review presents a brief overview of the general categories of commercially used proteases, and
critically surveys the successful strategies currently being used to improve the properties of prote-
ases for various commercial purposes. We describe the broad application of proteases in laundry
detergents, food processing, and the leather industry. The review also introduces the expanding
development of proteases as a class of therapeutic agents, as well as highlighting recent progress
in the ﬁeld of protease engineering. The potential commercial applications of proteases are rapidly
growing as recent technological advances are producing proteases with novel properties and sub-
strate speciﬁcities.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
It might come as a surprise to some that proteases, enzymes
that cleave other proteins or even themselves in catalytic fashion,
make up the largest single family of enzymes, constituting an esti-
mated 2% of the human genome [1,2]. Proteases are classiﬁed into
six groups: aspartate, cysteine, glutamate, metallo, serine, and
threonine [3] based on characteristic mechanistic features consis-
tent within each member of a group. Through structural and func-
tional diversity, proteases carry out a vast array of critical functions
ranging from intracellular protein recycling to nutrient digestion to
immune system cascade ampliﬁcation. The diversiﬁcation of the
biological roles of proteases stem from the evolution of countless
structural scaffolds to converge with similar active site geometries
with varied substrate recognition motifs. Despite their many dif-
ferent forms and functions, the underlying theme of peptide bond
scission by all proteases is the same: polarization of the scissile
amide C@O bond as well as activation of a nucleophilic group to at-
tack the carbonyl carbon leading to hydrolysis.
There is already a large array of commercially used proteases
ranging from detergent additives to effective therapeutics. The
therapeutic proteases have recently been nicely reviewed [4]. The
present review expands coverage to include the large variety of
other commercial protease classes. In general, current protease
products rely on naturally evolved cleavage speciﬁcities, althoughother properties such as solubility and overall stability have been
effectively engineered. Nevertheless, there is an incredible land-
scape of potential uses for engineered next generation proteases
once the power and speciﬁcity of their individual hydrolysis reac-
tions can be tailored for speciﬁc needs (Fig. 1). Thus, we will also
focus on recent advances in the engineering of new speciﬁcities
into existing proteases. The key idea here is that the apparent plas-
ticity of protease active sites has enabled them to evolve with vary-
ing degrees of substrate speciﬁcity and selectivity, thus making
proteases a promising framework with which to engineer unique
and useful new activities.
Most naturally occurring proteases are initially produced as
inactive precursors called zymogens. Some zymogens are acti-
vated by changes in the environment to induce a conformational
change or the binding of a small molecule/peptide to produce an
active conformation. A common strategy for zymogen activation
involves expression of the protease fused to an activation seg-
ment, ranging in size from 2 to 100 residues, which prevents pro-
teolytic activity until it is cleaved. The most common activation
segments are N-terminal sequences that sterically block the ac-
tive site. Beyond the role of sterically hindering the active site,
activation segments are often important for the folding, stability,
and sorting of the precursor protease [5]. Some interesting recent
work has focused on small molecule activators of several zymo-
gens, such as procaspases and zymogens of the ﬁbrinolytic and
coagulation systems [6,7]. Zymogen pro-domains have also been
engineered onto enzymes via alternate frame folding or circular
permutation, such as the conversion of the cytotoxic ribonuclease
barnase into an artiﬁcial zymogen activated by HIV-1 protease
[8,9].
Fig. 1. An overview of protease applications.
Fig. 2. Schematic diagram outlining the general approaches of protease engineering.
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of small molecule activators and inhibitors, peptides, receptors,
substrates, and binding domains, which also inﬂuence the spatial
and temporal localization of their activity. The human genome
contains over 550 presumed protease genes, the most abundant
of which are metallo, serine and cysteine proteases represented
by 191, 178 and 161 genes, respectively [10]. Threonine and aspar-
tic acid proteases are of a relatively low abundance with only 27
and 21 genes, respectively [10]. Recent advances in proteomics
have allowed researchers to gain a more comprehensive under-standing of protease expression, regulation and activity that is
now referred to as the degradome [11].
The goal of this review is to discuss the general categories of
commercial proteases then survey the successful strategies
(Fig. 2) now being used to improve protease properties, including
the engineering of entirely new substrate selectivities, for
industrial and therapeutic applications. The market for engineered
proteases is already large, but with the advent of a more wide-
spread ability to tailor stability, speciﬁcity and selectivity, the com-
mercial future of proteases appears very bright indeed.
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Proteases were ﬁrst applied in the detergent, leather and food
industries several hundred years ago. For instance, alkaline prote-
ases have been used to remove hair from hides, pancreatic protease
extracts for use in detergents and leather processing, proteases in
rennet from unweaned calves to coagulate milk for cheese produc-
tion, and papain from papayas to tenderize meat [12]. The unique
catalytic activities of proteases make them an inexpensive choice
for hydrolyzing peptide bonds for industrial uses. However, the
application of proteases for commercial use often requires them
to maintain high activity in non-physiological conditions such as
high temperatures and pH, intensive calcium chelating agents,
and detergents. The absence of such selection pressures during
the natural evolution of proteases means that most of them are
unstable or inactive in these non-physiological conditions. Prote-
ase engineering by site-directed mutagenesis or directed-evolution
can generate proteases with improved functions to meet the
requirements of commercial applications. The proteolytic enzyme
subtilisin [13], an important biocatalyst used in many detergent
formulations, will be mainly discussed in detail as a model case
study for the improvement of protease functions by protein
engineering.
2.1. Thermostability enhancement
High thermostability is a critical property required of proteases
for applications in laundry detergent or leather processing. Increas-
ing temperatures can disrupt the non-covalent interactions within
a folded protein, leading to protein unfolding [14]. During the
unfolding process, the exposure of buried hydrophobic residues
can potentially induce protein aggregation. Moreover, proteins
can also be inactivated through some covalent mechanisms, such
as deamidation of the Asn and Gln residues, hydrolysis of peptide
bonds, beta-elimination of disulﬁde bonds, and oxidation of cys-
teine and methionine residues. Protein engineering has provided
means to modulate protease stability to ﬁt desired requirements.
In general, a ﬁrst step when engineering proteins for enhanced
thermostability is to search for any naturally evolved stabilizing
residues by comparing the sequences of the corresponding homol-
ogous proteins from mesophiles and thermophiles. Additionally,
several other strategies of protein engineering have been exten-
sively explored.
2.1.1. Disulﬁde bonds
Introducing non-natural intramolecular disulﬁde bonds to sta-
bilize protein structure is one of the well-known strategies to in-
crease the stability of proteins. The additional intramolecular
disulﬁde bonds can lower the entropy of the unfolded polypeptide
chain, thus stabilizing the folded state. Based on structural com-
parison with a thermophilic subtilisin-type protease, aqualysin I,
an unnatural disulﬁde bridge of Cys-61/Cys-98 was introduced in
subtilisin E, resulting in a signiﬁcant enhancement of the thermal
stability [15]. A disulﬁde bond between Cys-22 and Cys-87 was
also reported to improve the stability of subtilisin BPN0, with a
more signiﬁcant effect in the absence of calcium [16]. In some
other cases, the introduction of disulﬁde bonds at incorrect posi-
tions may undermine the stability of proteases [17].
2.1.2. Amino acid modiﬁcation
Methionine, cysteine, or tryptophan residues close to or within
the active site of enzymes are normally involved in the oxidative
inactivation of the enzyme. Subtilisin was well known to be
inactivated by the oxidation of Met222, a catalytically important
residue, to its sulfoxide form. Estell et al. investigated the func-
tional consequences of replacing Met222 with the other 19 naturalamino acids [18]. Under non-oxidative conditions, the sulfur-con-
taining amino acids, Cys and Met exhibited the most speciﬁc activ-
ities towards the substrate, sAAPF-pNA, followed by the small
amino acids and amino acids with amides and aliphatic side
chains. Interestingly, under oxidizing conditions of 0.1 to 1.0 M
H2O2, replacement of Met 222 to non-oxidizable amino acids under
these conditions, Ala, Ser or Leu, improved the oxidative tolerance
of subtilisin. Based on the fact that the high speciﬁc activity of sub-
tilisin is linked to the presence of a sulfur atom at position 222,
Breddam and co-workers chemically modiﬁed an M222C mutant
by thiomethylating the cysteine with the thioalkylating reagent,
methyl methane thiosulfonate (Me-MTS) [19]. The engineered thi-
omethylated subtilisin derivative exhibited an extraordinarily en-
hanced stability and catalysis under oxidative conditions
compared to both wild-type and the unmodiﬁed M222C variant
during treatment with hydrogen peroxide. Thus, both mutagenesis
and chemical modiﬁcation are feasible strategies to engineer oxi-
dation-labile residues in proteases for improved oxidation-resis-
tant properties.
Other amino acid modiﬁcations, such as deamination of aspar-
agine, which is prone to occur via cyclization reactions with a C-
terminal glycine, also play important roles in protein inactivation
[20]. Narhi and colleagues described studies on the effect of point
mutations on the stability of aprA-subtilisin, which contains Asn-
Gly pairs at positions 109–110 and 218–219 [21]. The substitution
of N109S showed a 3 C increase in transition temperature, while
the substitution of N219S led to a 4 C increase in transition tem-
perature. Combination of these two mutations (N109S, N219S)
exhibited stability gains that had a cumulative beneﬁcial effect
on subtilisin stability, with a 7 C higher transition temperature.
2.1.3. Metal binding
Metal binding sites can function to both stabilize and activate
enzymes. For instance, a highly thermostable protease from Bacil-
lus sp. AK.1 in the subtilisin superfamily, is strongly stabilized by
binding three Ca2+ ions to speciﬁc sites in its tertiary structure
[22], preventing autolysis and thermal unfolding. Pantoliano
et al. explored the engineering of binding afﬁnity at metal ion bind-
ing sites for the stabilization of subtilisin [23]. Introducing nega-
tively charged Asp residues into the low-afﬁnity calcium-binding
site via substitutions at Gly131 and Pro172 strengthened the elec-
trostatic interaction between subtilisin and calcium ions, leading
to a signiﬁcant improvement in stability. On the other hand, engi-
neered subtilisin variants exhibiting high stability and catalytic
activity in the absence of calcium are required for use in laundry
detergents due to the high concentration of chelating agents pres-
ent in most brands. To solve this problem, an evolved subtilisin
variant, Sbt88, was isolated [24]. The calcium binding potential
was initially abolished by deleting the calcium-binding loop, fol-
lowed by improvement of the stability via directed evolution.
Sbt88 contained a 1000-fold greater stability in strong chelating
conditions with native-like catalytic activity [24]. Moreover, by
sequentially randomizing 12 amino acid positions in Sbt88, a
highly stable subtilisin variant, Sbt140, was obtained with a
15000-fold enhancement in its calcium-free half-life at elevated
temperatures [25].
2.2. Stability and activity enhancement in organic solvent
Industrial applications of enzymes can be greatly expanded if an
enzyme can perform in the presence of organic solvents rather
than just an entirely aqueous environment [26]. Proteases includ-
ing subtilisin have demonstrated their potential applications in or-
ganic synthesis [27], peptide synthesis [28], and enzymatic
esteriﬁcation of oligosaccharides [29] in anhydrous dimethylform-
amide (DMF). Principally, a layer of solvent water bound to the
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tional conformation when transferred from water to an organic
solvent [30]. However, water-miscible organic solvents, such as
DMF, can also strip away the layer of water associated with the
folded protein and destabilize the native protein [30]. Moreover,
organic solvents may also destabilize a reaction transition state,
thus decreasing the catalytic activity of the enzyme. As a powerful
strategy, protein engineering by directed evolution provides a
promising approach to recover the lost stability and catalytic activ-
ity of enzymes in organic solvent. Chen and Arnold generated a
randomly mutated library of subtilisin E by error prone PCR, and
screened the variant possessing enhanced catalytic activity of
hydrolyzing sAAPF-pNA in the presence of DMF [31]. A triple mu-
tant, D60N/Q103R/N218S, was identiﬁed with 38-fold improve-
ment in catalytic activity compared to wide-type subtilisin E in
85% DMF. To further tune the activity of subtilisin E, a variant con-
taining four effective substitutions (D60N/D97G/Q103R/N218S)
underwent sequential rounds of random mutagenesis and screen-
ing. Mutations with six additional amino acid substitutions
(G131D/E156G/N181S/S182G/S188P/T255A) were obtained, yield-
ing a 256-fold higher activity than wild-type subtilisin E in 60%
DMF [32].
3. Protease engineering in therapeutic applications
The concept of using engineered proteases for therapeutic
applications has long been a goal in the pharmaceutical industry.
The catalytic activity of proteases makes them a potentially unique
therapeutic, allowing for smaller dosages, the potential to inacti-
vate numerous target proteins and higher efﬁcacy. In combination,
these effects can lead to lower and less frequent dosages and more
importantly, lower costs. Various protease therapies are currently
under clinical investigation, a number of which are expected to
reach the market over the next few years. The FDA has already ap-
proved a variety of natural proteases for use in treatments such as
wound debridement (collagenase), thrombolysis (urokinase), hae-
mophilia (factor VIIa), sepsis (activated protein C) and muscle
spasms (botulinum toxin A and B) [4,33]. Of the therapeutic prote-
ases currently on the market, most are serine proteases, and only
two have been engineered for enhanced properties such as serum
half-life or stability [4]. To date, none have been engineered for en-
hanced selectivity or speciﬁcity. Tailoring protease speciﬁcity is an
important yet lofty goal in advancing the use of engineered prote-
ases as therapeutics.
3.1. Protein engineering to improve the efﬁcacy of therapeutic
proteases
Improving the efﬁcacy of therapeutic proteins is one of the ma-
jor objectives in protein engineering for therapeutic applications.
Notable successes in enhancing the efﬁcacy of therapeutic prote-
ases have so far only been achieved by rational design. For in-
stance, Novo Nordisk redesigned the residues in the activation
pocket of factor VIIa (FVIIa) by comparing the crystal structures
of selected trypsin family members, identifying ﬁve important
positions for the allosteric regulation of FVIIa activity [34]. One
of the engineered FVIIa variants (V158D/E296V/M298Q/L305V/
K337A) displayed 100-fold faster activity for TF-independent factor
X activation than the wild type protease, thus enhancing the proco-
agulant and anti-ﬁbrinolytic activities [34]. Another impressive
example of improved protease efﬁcacy was achieved by increasing
localization afﬁnity [35]. Interaction between the Gla domain of
factor VII and phospholipid membranes is essential for effective
hemostasis. Based on structural information of a vitamin K-depen-
dent protein with high membrane afﬁnity, Harvey et al. generateda FVII variant (Y4/P10Q/K32E/D33F/A34E) exhibiting a 150-fold
higher membrane binding afﬁnity and 40-fold enhanced factor X
activation by introducing more Gla domains at selected positions
in the membrane contact site. Multiple Gla domains enhanced
the interaction of factor VII with membranes containing acidic
phospholipids [35].
3.2. Protein engineering to improve the speciﬁcity of therapeutic
proteases
The potential of engineering proteases with narrowed speciﬁc-
ity to only one or a few target sequences should decrease side ef-
fects, while maintaining desired therapeutic beneﬁts. Bi-
functional thrombin presents a good example. It not only plays
an important role in activating multiple pro-coagulant substrates
in the blood-clotting pathway, but also acts as an anticoagulant
agent to attenuate clot formation by activating protein C when
bound to thrombomodulin on the vascular endothelium [36,37].
Thrombin has been engineered to enhance its speciﬁcity for its
anticoagulant functionality by restricting the interaction with
pro-coagulant substrates. Alanine scanning mutagenesis of the sol-
vent exposed charged and polar amino acids revealed that a single
substitution (E229A) could alter thrombin’s speciﬁcity to favor the
anticoagulant substrate, protein C [38]. In the cynomolgus monkey
model, the E229A mutant, acting as a selective endogenous protein
C activator, exhibited the function of reversible anticoagulation
without any procoagulant side effects. A thrombin double mutant
(W215A/E217A) was engineered to compromise its procoagulant
activities, exhibiting a 20000-fold slower kcat/KM for cleaving
ﬁbrinogen compared to that of wild-type thrombin, with compara-
ble speciﬁcity for activating protein C in the presence of thrombo-
modulin [39]. X-ray structural studies indicated that the W215A/
E217A mutations stabilized the E⁄ form, in which the E⁄–E equilib-
rium could only be substantially shifted by the binding of protein C
and thrombomodulin [40]. The treatment of platelet-dependent
thrombosis in a baboon model with the W215A/E217A mutant
exhibited safe and potent anticoagulant and antithrombotic effects
without any detectable hemorrhage or organ failure [41].
Activated protein C (APC) is another example of a bi-functional
protease in the blood coagulation system. Its dual mode of action
as an anticoagulant and anti-inﬂammatory agent beneﬁts septic
patients, and led to the development of Xigris, which is the ﬁrst
FDA-approved drug for severe sepsis. On the other hand, the bi-
functionality of Xigris complicates its clinical use. The anticoagu-
lant activity of the protease increases the risk of severe bleeding
events and patient death [42]. In order to minimize the undesired
side effects, considerable effort has been devoted to APC for selec-
tive alteration of the multiple activities by reducing its anticoagu-
lant properties while retaining its anti-inﬂammatory activity. It has
been shown that ﬁve basic residues in loop 37 and the Ca2+-bind-
ing loop of APC bind to factor Va, initiating cleavage at Arg-506 of
factor Va, generating its anticoagulant activity. However, these ﬁve
basic residues are not required for its cytoprotective effects. Mos-
nier et al. engineered an APC variant (RR229/230AA, KKK191-
193AAA) with smaller, neutral amino acid side chains on the
APC-factor Va contact surface, minimizing anticoagulant activity,
yet maintaining normal cytoprotective activities [43]. Moreover,
Bae et al. demonstrated that stabilizing the Ca2+-binding loop of
APC by an engineered disulﬁde bond (Cys67–Cys82) dramatically
abolished the anticoagulant activity of APC with little impact on
its cytoprotective and anti-inﬂammatory properties [44]. Another
successful strategy to eliminate the anticoagulant activity of APC
is via mutations within the Gla domain to disrupt the binding
interactions between APC and protein S cofactor. Harmon et al.
showed that a single mutation (L138D) in the Gla domain of APC
almost entirely abated its anticoagulant activity [45]. Such APC
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mance in severe sepsis therapy and are currently in preclinical
development.
3.3. Protein engineering to extend the serum half-life of therapeutic
proteases
Development of next generation therapeutic proteases with
prolonged half-lives will beneﬁt patients via reduced dosing fre-
quency. In general, protease inactivation by endogenous inhibition
has been implicated as a major cause of the short serum half-lives
of active therapeutic proteases. Understanding protease-inhibitor
interactions is especially signiﬁcant for therapeutic protease engi-
neering. Serpins use suicide-inhibition to inhibit proteases by gen-
erating a covalent complex with the protease. Disruption of serpin–
protease interactions can be applied to create an inhibitor-resistant
protease. Using tissue plasminogen activator (t-PA) as an example,
inhibitors of t-PA prevented systemic activation of plasminogen
and also attenuated the beneﬁcial therapeutic property of t-PA as
a thrombolytic agent [46]. Based on the known structural model
of trypsin, Madison et al. predicted that the residues of t-PA that
are in contact with plasminogen activator inhibitor-1 (PAI-1), are
not involved in the catalytic interactions with the substrate, plas-
minogen [47]. Wild type t-PA was completely inactivated by PAI-
1, while the mutant t-PA with a seven amino-acid (296–302) dele-
tion was capable of retaining 95% of its enzymatic activity under
the same conditions. In addition, heavy glycosylation of active
snake venom proteases appears to provide a steric barrier to inac-
tivation by inhibitors, leading to signiﬁcantly enhanced serum half-
lives [48]. By analogy, selective glycosylation of the residues
around a protease’s active site may provide an option for engineer-
ing therapeutic proteases with prolonged half-lives.
Another well-established technology for improving serum half-
lives of therapeutic proteins is the attachment of polyethylene gly-
col (PEG) chains that increase the hydrodynamic volume of pro-
teins, thus reducing the kidney clearance rate [49]. Other beneﬁts
from PEGylation include lowering immunogenicity, reducing pro-
tein aggregation, and improving protein thermal stability. In con-
trast to the random coupling of PEG groups to amino groups on
side chains, site-selective PEGylation, such as glycoPEGylation,
can generate homogeneous PEGylated proteins while preserving
bioactivity. Recombinant FVIIa and factor IX (FIX) have been engi-
neered via glycoPEGylation and are currently in Phase I clinical tri-
als for the treatment of hemophilia [50]. In a recent report, the
half-life of a glycoPEGylated FIX has been increased from 18 to
93 h in humans while maintaining the bioactivity of native FIX
[51]. Other general strategies to extend serum half-lives of thera-
peutic proteins include genetic fusion to a carrier protein with a
naturally long half-life, such as albumin or antibody-constant do-
main (Fc). CSL Behring applied the recombinant albumin fusion
technology to FVIIa to generate a fusion protein with a short and
ﬂexible glycine/serine linker, resulting in an extended half-life of
4.4 h in rat, which is 7-fold greater than that of wild-type FVIIa
[52]. A similar strategy was also used to engineer an FIX-albumin
fusion protein. In this case a cleavable linker was incorporated be-
tween the FIX and albumin moieties to avoid the interference of
FIX’s biological activity by the bulky albumin portion at the active
site. The FIX-albumin fusion, currently in a phase I/II clinical trial,
exhibited a 5-fold improved half-life over that of wild type FIX in
animal models, while providing sustained hemostatic efﬁcacy [52].
3.4. Protein engineering to reduce the immunogenicity of therapeutic
proteases
Although protein-based therapeutics hold great promise for the
treatment of human diseases and have expanded dramatically inthe last two decades, immunogenicity remains a problem. As a cat-
egory of protein-based therapeutics, proteases also face the same
clinical concerns of immunogenicity. The development of neutral-
izing antibodies to therapeutic proteases might attenuate the clin-
ical effect of the treatment, and may also result in serious life-
threatening adverse reactions. For instance, antibody induced ther-
apy failure (ABTF) is a big concern for botulinum toxins (BoNTs)
[53], which are FDA-approved therapeutics for the treatment of
various neurological disorders. Several strategies are being ex-
plored to reduce the risk factors for the immunogenicity of BoNTs,
including limiting the BoNT drug’s protein load, improving drug
formulation to remove the complexing proteins, development of
high afﬁnity BoNT, and shielding antigenic BoNT epitopes [54]. In
addition, other general strategies for reducing immunogenicity
by protein engineering take advantage of modifying proteins by
glycosylation or PEGylation, fusing therapeutic protein to a human
Ig Fc fragment, and minimizing T cell epitopes by mutagenesis
[55–58].
4. Practical considerations of protease engineering
4.1. Protease engineering through structure-guided mutagenesis
Since 1982, when site-directed mutagenesis was ﬁrst used to
engineer enzymes with known structure [59], extraordinary
achievements have been accomplished for the enhancement of
the innate properties of proteases such as catalytic activity and sta-
bility (Fig. 2) [34,47,60,61]. Although the achievements obtained
with subtilisin and human coagulation factors, as mentioned
above, have had a measurable positive impact, it can still be argued
that the wider application of commercial proteases has been lim-
ited in part because little progress has been made toward altering
protease substrate speciﬁcity.
The ﬁrst landmark progress on altering substrate speciﬁcity was
achieved with trypsin twenty years ago [62]. Based on the similar-
ity in tertiary structures of trypsin and chymotrypsin, trypsin was
engineered to be a chymotrypsin-like protease via key residue
replacements in the S1 binding pocket as well as a critical surface
loop. This trypsin variant presented chymotrypsin-like substrate
binding patterns, differentiating substrates in the acylation step
during the catalysis. In addition, computer graphic analysis was
also used to guide the engineering of trypsin to increase its speci-
ﬁcity to arginine and lysine substrate [63]. Further research has fo-
cused on the surface loops [64] and S10 subsite [65] broadening the
application of the engineered trypsin.
Subtilisin is another excellent example, which has been suc-
cessfully engineered for various purposes. After altering the sub-
strate speciﬁcity to dibasic residues [66], subtilisin BPN0 was
further engineered to resemble furin, called furilisin, that could
cleave tribasic substrates after site-mutagenesis in the residues
that consisted of the S4 subsites in subtilisin [67]. 3-D structure
modeling using the published structures of different proteases re-
vealed that two crucial residues, Gly124 and Gly152, which are lo-
cated on both sides of the waist of the S1 pocket, were involved in
the substrate speciﬁcity alteration of subtilisin YaB [68]. Mutations
of these two residues signiﬁcantly enhanced protease activity.
Other examples of successful subtilisin engineering include substi-
tution of its catalytic histidine with alanine to increase the prote-
ase speciﬁcity against histidine-containing substrates [69], and
the alteration of substrate speciﬁcity at the P4 subsite [70,71].
Extending beyond the ground-breaking accomplishments of the
engineered trypsin and subtilisin variants, other proteases have
been successfully engineered based on making changes inspired
by structural and sequence comparisons. Examples include swap-
ping substrate speciﬁcities of the neuropeptidase, neurolysin, and
thimet oligopeptidase [72], enhancing the P1 substrate speciﬁcity
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speciﬁcity of porcine pepsin to resemble fungal aspartic endopetid-
ases [74]. The S2 subsite speciﬁcity of several other proteases were
also altered in this way, such as the engineering of papain [75], hu-
man cathepsin S [76], human cathepsin D [77] and aqualysin I [78].
Although these and similar efforts pioneered the ﬁeld of protease
engineering, generating protease variants with truly novel sub-
strate speciﬁcities not found in homologs has remained more
elusive.
4.2. Protease engineering via directed evolution
An approach to the isolation of engineered proteases with en-
tirely new properties, such as substrate speciﬁcities not found in
homologs, involves the use of directed evolution (Fig. 2). In the di-
rected evolution approach, proteases with desirable properties are
derived from libraries of protease variants having various levels of
sequence randomization. Two signiﬁcant challenges are often
encountered when trying to engineer new sequence speciﬁcity into
a protease. First, multiple simultaneous mutations can be required
to alter substrate speciﬁcity, necessitating the use of relatively
large libraries of protease variants to insure that rare mutation
combinations are present. Second, the directed evolution of en-
zyme function commonly leads to enzyme variants showing pro-
miscuous rather than speciﬁcally altered substrate speciﬁcity. To
overcome these two obstacles, various high-throughput screening
methods have been developed in Escherichia coli and yeast plat-
forms over the last ten years (Table 1).
4.2.1. Directed evolution and high-throughput screening of proteases
in E. coli-based systems
As a directed evolution platform, E. coli has several technical
advantages including high transformation efﬁciencies and a fast
growth rate. Several E. coli based methods have been developed
that successfully alter protease activity (Table 1). For example, a
method based on b-galactosidase inactivation relied on the obser-
vations of different X-gal degradation rates to isolate evolved pro-
teases with desired substrate speciﬁcities [79]. In this approach,
the designed substrate sequence was inserted into an accessible
surface loop of b-galactosidase. Cleavage of the substrate sequence
leads to a decrease in b-galactosidase activity. An HIV-1 protease
(HIV PR) variant, which displayed a 2-fold increase in preference
for a novel substrate with low cellular toxicity, was isolated via this
approach. Another E. coli method utilized a genetic selection sys-
tem (GSS) to engineer variants of the tobacco etch virus protease
(TEV-P) with speciﬁcities favoring nominally poor substrates of
wild-type TEV-P [80]. The desired new substrate sequence was in-
serted between two DNA-binding domain (DBD) moieties. Cleav-
age by a TEV-P variant resulted in the enhanced expression of
reporter genes, such as HIS3, kanamycin resistance gene, and LacZ.
These genes facilitated the host’s growth rate and an increase in b-
galactosidase activity. A TEV-P variant was evolved using this
method with an altered P10 speciﬁcity. Note that both of these
methods required isolation of individual colonies on plates,Table 1
Pioneer work of the next generation protease engineering.
System Host Reaction Location Concept
b-gal inactivation E. coli Cytoplasm X-gal selection/ cell growth
GSS E. coli Cytoplasm Cell growth rate/ report ge
ssrA E. coli Cytoplasm GFP degradation /FACS
OmpT E. coli Cell Surface Electrostatic cells surface/F
YBGA Yeast Cytoplasm Cell growth rate
GASP Yeast Cytoplasm Transcription enhancer/X-g
GSS: genetic selection system; YBGA: yeast-based growth assay; GASP: genetic assay folimiting throughput. In addition, no ability to include a simulta-
neous counter-selection substrate screen into the assay was re-
ported, making it impossible to exclude the more common
promiscuous enzymes from the pool of those isolated. Finally,
any protease activity that interfered with E. coliwould likely be ex-
cluded from those isolated.
Directed evolution based upon E. coli in combination with ﬂuo-
rescence activated cell sorting (FACS) has proven to be the most
proliﬁc directed evolution-based protease engineering approach
yet reported. It has been used to engineer a variety of new sub-
strate selectivities into OmpT, an E. coli outer membrane protease,
in a surprising general way, and without sacriﬁcing overall cata-
lytic activity. In the E. coli-FACS system, the negative charge of
the E. coli outer surface is exploited to capture positively-charged
and ﬂuorescently-labeled cleavage products. Fluorescence inten-
sity measured by FACS is proportional to catalytic turnover, provid-
ing a way to quantify and isolate the fastest protease variants in
high throughput fashion from libraries exceeding 108 members.
Multiple substrates, each containing a different cleavage sequence
as well as a differently colored ﬂuorophore, can be used with mul-
ti-color FACS to screen directly for highly speciﬁc variants that
cleave only desired substrate sequences. Thus, the E. coli based
FACS system can address both of the critical issues related to pro-
tease engineering through directed evolution described at the
beginning of this section; namely, the ability to screen relatively
large libraries as well as the ability to incorporate simultaneous
counter selection substrates along with the selection substrate,
insuring that relatively sequence-selective protease variants are
isolated [81,82].
The E. coli-FACS system was used to isolate a number of OmpT
variants that speciﬁcally prefer substrates with novel P1 and/or P10
residues. Importantly, a relatively high level of catalytic activity
along with the new selectivity was observed with all of these vari-
ants, demonstrating the plasticity of the OmpT active site [81–85].
Perhaps surprisingly, OmpT variants preferring neutral and even
acidic residues at P1 and P10 were isolated. Wild-type OmpT pre-
fers dibasic residues, especially Arg, at these critical substrate posi-
tions. Thus, relatively dramatic alteration of substrate speciﬁcity,
including the reversal of substrate charge at the site of cleavage,
has been achieved with the same protease. Further, OmpT variants
were engineered to speciﬁcally cleave substrates containing post-
translationally modiﬁed tyrosine residues at P1, namely sulfotyro-
sine [84] and nitrotyrosine [85]. A subtilisin variant engineered to
cleave speciﬁcally after phosphotyrosine has also been reported
[86]. In each case, the engineered protease variants preferred the
modiﬁed substrates over unmodiﬁed tyrosine. Since no protease
with a naturally evolved speciﬁcity for post-translationally modi-
ﬁed amino acids has been reported, the engineering of such novel
and highly specialized variants predicts a bright future for those
attempting to reprogram the substrate selectivities of proteases.
A different E. coli based system has been reported that exploits
the sequence dependent ClpXP-mediated degradation pathway
[87]. In particular, appending the so-called ssrA sequence to a pro-
tein targets that protein for rapid degradation. To generate aEvolved Protease Alteration of the Substrate Speciﬁcity Ref.
HIV-PR 2-fold change [79]
ne TEV-P P10 speciﬁcity, 100-fold change [80]
TEV-P NA [87]
ACS OmpT 105–107-fold change [82]
TEV-P NA [83]
al HAV 3CP P2 speciﬁcity, 160-fold change [90]
r site-speciﬁc proteolysis.
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ase substrate sequence is inserted between the ssrA sequence and
green ﬂuorescent protein (GFP). If there is no cleavage by an added
protease or protease variant, the ssrA tag leads to rapid degrada-
tion of GFP in the cytoplasm, preventing the folding of GFP and
its transport to the periplasm. Cleavage by the protease removes
the ssrA tag, so the GFP is successfully transported to the periplasm
and the cells become ﬂuorescent, enabling high throughput isola-
tion by FACS. This approach is still relatively new and no compre-
hensive protease engineered using it has been reported. However,
the substrate proﬁling of the wild-type TEV-P was performed [87].
4.2.2. Directed evolution and high-throughput screening of proteases
in yeast-based systems
The OmpT system is a powerful tool and platform for protease
engineering, but it is not without drawbacks. This strategy is lim-
ited to enzymes that can be displayed in an active form on the sur-
face of E. coli, an important constraint in the engineering of most
proteases, especially eukaryotic proteases [88,89]. Because the pro-
tein folding and secretory pathways of yeast more closely approx-
imate those of mammalian cells compared to E. coli, such as
promoting efﬁcient oxidative protein folding and N-linked glyco-
sylation, methods were developed in yeast with the purpose of
engineering eukaryotic proteases. As of yet, only twomethods have
been reported on the engineering of proteases in a yeast-based
platform (Table 1), more than likely due to the complexity of
manipulation in yeast.
The yeast-based growth assay (YBGA) was the ﬁrst high-
throughput screening method reported in yeast [83]. In YBGA, a
temperature sensitive Saccharomyces cerevisiae strain, CDC25-2,
was used as the host to isolate the evolved proteases. The
CDC25-2 cells can only grow at the non-permissive temperature
of 36 C in the presence of an active protease variant against the
designed substrate in the cells. The concept of the YBGA was well
demonstrated with wild-type TEV-P, however, no engineered TEV-
P variants with novel speciﬁcities were reported using this method.
The yeast GASP (genetic assay for site-speciﬁc proteolysis) sys-
tem is another reported method for protease engineering in yeast
[90,91]. In brief, the LexA-b42 moiety, which is a plasma mem-
brane-anchored triple fusion protein (STE2-substrate-LexA-b42),
can be released to activate the expression of the LexA operon reg-
ulated reporter genes, such as Leu2 and LacZ, in the presence of an
active protease variant. Using the yeast GASP approach, Sellamu-
thu and his colleagues successfully altered the substrate speciﬁcity
for the P2 position of HAV 3CP [90], and further evolved the HAV
3CP to recognize the Q8 substrate (QQQQQ/QQQ) [91].
Although novel high-throughput screening methods signiﬁ-
cantly expedite the development of protease engineering, several
challenges still exist. The size of the mutant library is currently
limited to less than 1010 in most of the methods, which can only
cover the saturated mutagenesis of 7 residues. However, multiple
mutations are often required to alter substrate speciﬁcity. In the
case of engineered OmpT, changing the P1 speciﬁcity required as
many as nine mutations around the substrate-binding pocket
[85]. The limited mutant library size signiﬁcantly lowers the odds
of isolating a desired variant. In order to cover as many residues,
yet maintain a similar sized library, a computationally designed
‘‘smart library’’, based on the known three-dimensional structure,
should be applied in combination with the high-throughput
screening methods. In addition, the E. coli- and yeast-based plat-
forms have their disadvantages of being unfavorable for the
expression, folding, and post-translational modiﬁcations of human
proteins. Because of the potential of therapeutic applications of hu-
man proteases, a more powerful high-throughput screening meth-
od, which could be generally applied to all proteases, especially
human proteases, is still needed.5. Future directions
The applications of proteases in industry and therapeutics have
grown rapidly in the last two decades. Novel protein engineering
strategies and techniques will continue to expand the commercial
protease markets. Encouragingly, the recent success of apoptotic
caspase activation with engineered small-molecule-activated pro-
teases [92] represents a new way to speciﬁcally control human
protease activity for clinical applications. In addition, taking advan-
tage of the proteolytic activities of proteases in diseased tissues
may also offer a new strategy for site-speciﬁc drug targeting [93]
and tumor imaging [94]. With the development of synthetic biol-
ogy, computational design, crystallography, and screening technol-
ogies, we can anticipate that the future of protease engineering
will be a multi-disciplinary task with many dramatic successes to
come.
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